TNXP Tonix Pharmaceuticals Holding Corp.

0.91
-0.05  -5%
Previous Close 0.96
Open 0.92
52 Week Low 0.3902
52 Week High 2.46
Market Cap $240,947,298
Shares 264,777,250
Float 264,749,904
Enterprise Value $186,495,297
Volume 30,008,285
Av. Daily Volume 13,830,794
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
TNX-102 SL (Tonmya)
Fibromyalgia
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Tonmya (TNX-102 SL)
Post-traumatic stress disorder (PTSD)
Phase 3
Phase 3
Phase 3 enrolment to be stopped due to futility - February 5, 2020. Top-line data confirmed primary endpoint was not met - December 21, 2020.
TNX-102 SL
Alcohol Use Disorder
Phase 2
Phase 2
Phase 2 ready.
TNX-1800
COIVD-19 vaccine
Phase 1
Phase 1
Phase 1 trial to be initiated in 2021.
TNX-102 SL (Tonmya)
Post-traumatic stress disorder (PTSD)
Phase 3
Phase 3
Phase 3 trial halted due to insufficient efficacy - July 27, 2018.
TNX-201
Episodic tension-type headache
Phase 2
Phase 2
Phase 2 data released February 2016 did not meet primary endpoint

Latest News

  1. GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021

    CHATHAM, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the World Intellectual Property Organization has published a patent application filed under the Patent Cooperation Treaty covering TNX-1500, a humanized monoclonal antibody (mAb) directed against CD40-ligand, which is also known as CD154, T-BAM, 5c8 antigen, TRAP and gp39. The patent application is titled "Anti-CD154 Antibodies and Uses Thereof" and published under International Publication No. WO 2021/001458 A1. If claims are granted, a patent issuing from a national stage…

    GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021

    CHATHAM, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the World Intellectual Property Organization has published a patent application filed under the Patent Cooperation Treaty covering TNX-1500, a humanized monoclonal antibody (mAb) directed against CD40-ligand, which is also known as CD154, T-BAM, 5c8 antigen, TRAP and gp39. The patent application is titled "Anti-CD154 Antibodies and Uses Thereof" and published under International Publication No. WO 2021/001458 A1. If claims are granted, a patent issuing from a national stage of this application could potentially provide U.S. patent coverage for the TNX-1500 composition of matter through 2040 excluding possible patent term extensions or patent term adjustments.

    Tonix's President and Chief Executive Officer, Seth Lederman, M.D. said, "Nearly 30 years ago my laboratory at Columbia University generated the first anti-CD40-ligand mAb (5c8), discovered and characterized human CD40-ligand and elucidated the molecular basis of T cell helper function1. Collaborating with a team at Biogen Inc., we determined the crystal structure of CD40-ligand2, developed a humanized version of our antibody (hu5c8, ruplizumab, or Antova®) and tested it in human trials for preventing organ transplant rejection and autoimmunity. Our studies and those of others generated a substantial body of evidence in humans and animals that indicates anti-CD40-ligand mAbs have the potential to be an important therapeutic option for preventing or treating transplant organ rejection and for treating autoimmune disorders."

    Dr. Lederman continued, "Despite the recognized promise of anti-CD40-ligand mAb therapy, first generation anti-CD40-ligand mAbs were limited because their crystallizable fragment (Fc) domain interacted with a cell surface receptor called FcγRII, which resulted in an increased risk of thrombosis. Second generation anti-CD40-ligand mAbs had dramatically reduced binding to FcγRII, but had other issues, including decreased efficacy3-5. TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease FcγRII binding and the potential for thrombosis, while retaining efficacy. We believe TNX-1500 has the potential for treating and preventing organ transplant rejection and treating autoimmunity."

    TNX-1500 incorporates the antigen binding fragment (Fab) region of hu5c8, which has been extensively characterized including at the atomic level in complex with CD40-ligand6. The newly published patent application includes claims related to proprietary anti-human CD40-ligand mAbs that were engineered to have modified effector function, including TNX-1500, which have reduced potential for Fc binding to FcγRII. The patent application also claims uses of TNX-1500 for preventing and treating conditions, such as organ transplant rejection and autoimmune disorders.

    Dr. Lederman added, "We believe the development risk of TNX-1500 is mitigated by previous clinical data and extensive preclinical science with ruplizumab. We are developing the manufacturing processes for TNX-1500 and expect Good Manufacturing Practice (GMP) TNX-1500 to be available in the third quarter of 2021. There remains a significant need for new treatments with improved activity and tolerability to prevent or treat organ transplant rejection and to treat autoimmune conditions, including systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis."

    1 Lederman, S. et al. J. Exp. Med. 175:1091-1101 (1992)

    2 Karpusas, M et al., Structure 3:1031-1039 (1995)

    3 Waters J, Biocentury; October 26, (2018)

    4 NCT02273960; ClinicalTrials.gov; "Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)"; results posted April 1, 2019, updated July 29, 2019 and accessed Jan 11, 2021

    5 Ferrant JL et al., International Immunol. (11):1583 (2004)

    6 Karpusas M, et al. Structure. 9(4):321-9. (2001)

    About CD40-Ligand

    CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. CD40-ligand is also known as CD154, the T cell-B cell activating molecule (T-BAM), TRAP and gp39. CD154 is a member of the Tumor Necrosis Factor (TNF) Super Family. No mAb against CD154 has been approved for commercial use anywhere in the world. Other TNF Super Family members have been successfully targeted by antagonist mAbs. Approved mAbs against TNFα include: infliximab (Remicade®), adalimumab (Humira®), certolizumab pegol (Cimzia®), and golimumab (Simponi®) for the treatment of certain autoimmune conditions. Also, etanercept (Enbrel®) is a TNFα antagonist receptor fusion protein. An approved mAb against RANKL (CD254) is denosumab (Prolia® or Xgeva®) for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

    Remicade® and Simponi® are trademarks of Janssen; Humira® is a trademark of AbbVie Inc.; Cimzia® is a trademark of UCB S. A.; Enbrel®, Prolia® and Xgeva® are trademarks of Amgen Inc.

    Tonix Pharmaceuticals Holding Corp.

    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL*, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data for the Phase 3 RALLY study in the second quarter of 2021** and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-1800***, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801***, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.

    *TNX-102 SL is an investigational new drug and has not been approved for any indication.



    ** Pending submission and agreement from FDA on statistical analysis plan.

    ***TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.

    This press release and further information about Tonix can be found at www.tonixpharma.com.

    Forward Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (the "SEC") on March 24, 2020, and periodic reports filed with the SEC on or after the date thereof. All Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Contacts

    Jessica Morris (corporate)

    Tonix Pharmaceuticals

     

    (862) 904-8182

    Olipriya Das, Ph.D. (media)

    Russo Partners

      

    (646) 942-5588

    Peter Vozzo (investors)

    Westwicke

     

    (443) 213-0505



    Primary Logo

    View Full Article Hide Full Article
  2. CHATHAM, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ:TNXP) ("Tonix" or the "Company"), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of $40.0 million before deducting fees and other estimated offering expenses.

    The Company sold 50,000,000 shares of common stock at $0.80 per share. A.G.P./Alliance Global Partners acted as sole placement agent for the offering.

    This offering was made pursuant to effective shelf registration statements on Form S-3 (File No. 333-224586 and 333-237610) previously filed and declared effective by the U.S. Securities and Exchange Commission (the "SEC…

    CHATHAM, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ:TNXP) ("Tonix" or the "Company"), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of $40.0 million before deducting fees and other estimated offering expenses.

    The Company sold 50,000,000 shares of common stock at $0.80 per share. A.G.P./Alliance Global Partners acted as sole placement agent for the offering.

    This offering was made pursuant to effective shelf registration statements on Form S-3 (File No. 333-224586 and 333-237610) previously filed and declared effective by the U.S. Securities and Exchange Commission (the "SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A final prospectus relating to the offering was filed with the SEC on January 12, 2021 and is available on the SEC's website located at http://www.sec.gov. Copies of the prospectus supplement, together with the accompanying prospectuses, can be obtained at the SEC's website at www.sec.gov or from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, New York 10022 or by email at .

    About Tonix Pharmaceuticals Holding Corp.

    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL*, is in mid-Phase 3 development for the management of fibromyalgia since positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data for the Phase 3 RALLY study in the second quarter of 2021** and topline data in the Phase 3 RALLY study in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-1800***, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801***, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.

    *TNX-102 SL is an investigational new drug and has not been approved for any indication.

    ** Pending submission and agreement from the U.S. Food and Drug Administration (FDA) on the statistical analysis plan.

    ***TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.

    This press release and further information about Tonix can be found at www.tonixpharma.com.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, statements about the closing of the offering; gross proceeds from the offering; risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; substantial competition and other risks and uncertainties detailed in Tonix's Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission ("SEC") on March 24, 2020, as well as Tonix's subsequent periodic and current report filed with the SEC. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 24, 2020, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Contacts

    Jessica Morris (corporate)

    Tonix Pharmaceuticals



    (862) 904-8182

    Olipriya Das, Ph.D. (media)

    Russo Partners



    (646) 942-5588

    Peter Vozzo (investors)

    Westwicke



    (443) 213-0505



    Primary Logo

    View Full Article Hide Full Article
  3. Presentation Times and Weblinks Released for Over 60 Presenting Companies

    NEW YORK, NY / ACCESSWIRE / January 13, 2021 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs, for its two-day Winter 2021 Virtual Investor Conference, to take place Wednesday and Thursday, January 13-14, 2021. The links can also be found at www.sidoticonference.com/events.

    Sidoti & Co. Winter 2021 Microcap Conference - Virtual Agenda

    Day 1 - Wednesday, January 13, 2021

    8:30-9:00

    ****

    ****

    ****

    ****

    9:15-9:45

    Tonix Pharmaceuticals (TNXP)

    Circor International (CIR)

    Intelligent Systems
    (INS)

    ****

    10:00-10:30

    Protech Home Medical (PTQ.V)

    The Eastern Company (EML)

    Braemer Hotels & Resorts
    (BHR)

    SWM International (SWM)

    10:45-11:15

    VolitionRx Limited (VNRX)

    Presentation Times and Weblinks Released for Over 60 Presenting Companies

    NEW YORK, NY / ACCESSWIRE / January 13, 2021 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs, for its two-day Winter 2021 Virtual Investor Conference, to take place Wednesday and Thursday, January 13-14, 2021. The links can also be found at www.sidoticonference.com/events.

    Sidoti & Co. Winter 2021 Microcap Conference - Virtual Agenda

    Day 1 - Wednesday, January 13, 2021

    8:30-9:00

    ****

    ****

    ****

    ****

    9:15-9:45

    Tonix Pharmaceuticals (TNXP)

    Circor International (CIR)

    Intelligent Systems
    (INS)

    ****

    10:00-10:30

    Protech Home Medical (PTQ.V)

    The Eastern Company (EML)

    Braemer Hotels & Resorts
    (BHR)

    SWM International (SWM)

    10:45-11:15

    VolitionRx Limited (VNRX)

    Orion Group Holdings (ORN)

    Information Services Group (III)

    VSE Corporation (VSEC)

    11:30-12:00

    Otter Tail Corporation (OTTR)

    Culp, Inc. (CULP)

    Forrester Research (FORR)

    ****

    12:15-12:45

    Carriage Services, Inc. (CSV)

    ESCO Technologies Inc. (ESE)

    DHI Group, Inc.
    (DHX)

    Brady Corporation
    (BRC)

    1:00-1:30

    Hooker Furniture Corporation
    (HOFT)

    Quaker Houghton
    (KWR)

    ****

    ABM Industries (ABM)

    1:45-2:15

    Helius Medical Technologies, Inc. (HSDT)

    Balchem Corporation (BCPC)

    Mistras Group
    (MG)

    Charles River Associates (CRAI)

    2:30-3:00

    Safehold Inc. (SAFE)

    PyroGenesis Canada Inc

    BioSig Technologies, Inc. (BSGM)

    Willdan Group (WLDN)

    3:15-3:45

    SuRo Capital (SSSS)

    Powell Industries, Inc. (POWL)

    OneSoft Solutions Inc. (OSS.V)

    Heidrick & Struggles (HSII)

    4:00-4:30

    Axos Financial, Inc.
    (AX)

    Capstone Turbine Corporation (CPST)

    A10 Networks (ATEN)

    Resources Connection (RGP)

    1x1s Only

    (13th)

    Astec Industries (ASTE)

    CSW Industrials (CSWI)

    Heritage Insurance Holdings (HRTG)

    Kimball Electronics (KE)

    Matson, Inc. (MATX)

    Sidoti & Co. Winter 2021 Microcap Conference - Virtual Agenda

    Day 2 - Thursday, January 14, 2021

    8:30-9:00

    ****

    ****

    Golden Valley Mines Ltd. (GZZ.V)

    Eagle Bulk Shipping (EGLE)

    9:15-9:45

    International Seaways (INSW)

    Gibraltar Industries (ROCK)

    Comtech Telecommunications (CMTL)

    Osisko Gold Royalties (OR)

    10:00-10:30

    Matrix Service Company (MTRX)

    ****

    Luxfer Holdings PLC (LXFR)

    Unisys Corporation
    (UIS)

    10:45-11:15

    LeMaitre Vascular (LMAT)

    AAON Inc. (AAON)

    VersaBank (VB.TO)

    Good Natured Products (GDNP.V)

    11:30-12:00

    Varex Imaging Corp. (VREX)

    Apogee Enterprises (APOG)

    Civeo Corporation (CVEO)

    ****

    1x1s Only

    (14th)

    Commercial Vehicle Group (CVGI)

    Heritage Insurance Holdings (HRTG)

    Methode Electronics (MEI)

    Plexus Corp (PLXS)

    Quanex Building Products (NX)

    Please join our friends at Friedman LLP (www.friedmanllp.com) next week, for two valuable tax webinars: "Mapping out the New Stimulus Bill" on January 19th and "COVID-19 Impact on State Residency: Tax Opportunities & Pitfalls" on January 21st. To register please click here.

    About Sidoti
    For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on small- and micro-cap companies and the institutions that invest their securities, with most of our coverage in the $100 million - $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a small-and micro- cap focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. We serve 500+ institutional clients in the U.S., Canada and the U.K., including many leading managers of portfolios with $200 million to $2 billion of AUM. Sidoti promotes meaningful interaction between issuers and investors in the small- and micro-cap space through our conferences www.sidoticonference.com and the hundreds of non-deal roadshows we host each year.

    Contact
    Sidoti Events Team
    212-453-7031

    SOURCE: Sidoti & Company, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/624038/Sidoti-Virtual-Investor-Conference

    View Full Article Hide Full Article
  4. CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ:TNXP) ("Tonix" or the "Company"), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 50,000,000 shares of common stock, par value $0.001 per share at an offering price of $0.80 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The gross proceeds of the offering will be $40,000,000 before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about January 13, 2021, subject to the satisfaction of customary closing…

    CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ:TNXP) ("Tonix" or the "Company"), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 50,000,000 shares of common stock, par value $0.001 per share at an offering price of $0.80 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The gross proceeds of the offering will be $40,000,000 before deducting fees and other estimated offering expenses. The closing of the registered direct offering is expected to take place on or about January 13, 2021, subject to the satisfaction of customary closing conditions. 

    A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

    This offering was made pursuant to effective shelf registration statements on Form S-3 (File No. 333-224586 and 333-273610) previously filed with and declared effective by the U.S. Securities and Exchange Commission (the "SEC").  This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  A prospectus supplement relating to the shares of common stock will be filed by Tonix with the SEC.  When available, copies of the prospectus supplement, together with the accompanying prospectuses, can be obtained at the SEC's website at www.sec.gov or from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, New York 10022 or by email at .

    About Tonix Pharmaceuticals Holding Corp.

    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL*, is in mid-Phase 3 development for the management of fibromyalgia since positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data for the Phase 3 RALLY study in the second quarter of 2021** and topline data in the Phase 3 RALLY study in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-1800***, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801***, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.

    *TNX-102 SL is an investigational new drug and has not been approved for any indication.

    ** Pending submission and agreement from the U.S. Food and Drug Administration (FDA) on the statistical analysis plan.

    ***TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.

    This press release and further information about Tonix can be found at www.tonixpharma.com.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, statements about the expected closing of the offering; anticipated gross proceeds from the offering; risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; substantial competition and other risks and uncertainties detailed in Tonix's Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission ("SEC") on March 24, 2020, as well as Tonix's subsequent periodic and current report filed with the SEC. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 24, 2020, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Contacts

    Jessica Morris (corporate)

    Tonix Pharmaceuticals



    (862) 904-8182

    Olipriya Das, Ph.D. (media)

    Russo Partners



    (646) 942-5588

    Peter Vozzo (investors)

    Westwicke



    (443) 213-0505



    Primary Logo

    View Full Article Hide Full Article
  5. CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at four upcoming virtual conferences in January.

    EventH.C. Wainwright BioConnect Conference
    DateJanuary 11-14, 2021
    TimePresentation available on demand January 11-14, 2021
      
    EventBiotech Showcase 2021
    DateJanuary 11-15, 2021
    TimePresentation available on demand January 11-15, 2021
      
    EventSidoti Winter Virtual Investor Conference  
    DateWednesday, January 13, 2021  
    Time9:15 a.m. ET  
      
    EventICR Conference 2021  
    DateThursday, January 14, 2021  
    Time9:15 a.m. ET  

    Webcasts of the H.C…

    CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at four upcoming virtual conferences in January.

    EventH.C. Wainwright BioConnect Conference
    DateJanuary 11-14, 2021
    TimePresentation available on demand January 11-14, 2021
      
    EventBiotech Showcase 2021
    DateJanuary 11-15, 2021
    TimePresentation available on demand January 11-15, 2021
      
    EventSidoti Winter Virtual Investor Conference  
    DateWednesday, January 13, 2021  
    Time9:15 a.m. ET  
      
    EventICR Conference 2021  
    DateThursday, January 14, 2021  
    Time9:15 a.m. ET  

    Webcasts of the H.C. Wainwright, Sidoti and ICR conferences presentations will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com.

    About Tonix Pharmaceuticals Holding Corp.

    Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL*, is in mid-Phase 3 development for the management of fibromyalgia since positive data on the RELIEF Phase 3 trial were recently reported. The Company expects topline data in the Phase 3 RALLY study in the fourth quarter of 2021.  The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-1800**, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801**, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.

    *TNX-102 SL is an investigational new drug and has not been approved for any indication.

    **TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.

    This press release and further information about Tonix can be found at www.tonixpharma.com.

    Jessica Morris (corporate)

    Tonix Pharmaceuticals



    (862) 904-8182

    Olipriya Das, Ph.D. (media)

    Russo Partners



    (646) 942-5588

    Peter Vozzo (investors)

    Westwicke, an ICR Company



    (443) 213-0505



    Primary Logo

    View Full Article Hide Full Article
View All Tonix Pharmaceuticals Holding Corp. News